Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Sugen's strategy: a signal for P&U purchase

Nature Biotechnology volume 17, pages 745–746 (1999)Cite this article

With financing from Wall Street still sparse, biotechnology companies continue to look to collaborations with big pharmaceutical companies or larger biotech companies in order to access much-needed resources. In mid-June, Pharmacia & Upjohn (P&U; Bridgewater, NJ) agreed to acquire the signal transduction concern, Sugen (South San Francisco, CA), in a deal valued at $650 million. Sugen managed to secure a healthy price tag thanks in part to a strategy of refusing to license out early-stage products.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Author information

Author notes

  1. Vicki Glaser is a freelance writer working in Allentown, PA.

    • Vicki Glaser
Authors
  1. Vicki Glaser
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Glaser, V. Sugen's strategy: a signal for P&U purchase. Nat Biotechnol 17, 745–746 (1999). https://doi.org/10.1038/11670

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/11670

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing